Shanghai, China

Wei Deng

This inventor holds 24 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 10 EPO patents, primarily in Automotive Safety Devices. Top assignees: Ningbo Xuli Metal Products Co., Ltd., Hutchison Medipharma Limited, Purdue Research Foundation. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wei Deng. Retrieved from https://idiyas.com/inventor/wei-deng-va0cnmyz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 

% Patents Active = 79.2

 

 

Average Co-Inventor Count = 3.6

ph-index = 2

Forward Citations = 25(Granted Patents)


Location History:

  • Shanghai, CN (2011 - 2020)
  • Zhejiang, CN (2016 - 2024)
  • Ningbo, CN (2018 - 2024)

Company Filing History:


Years Active: 2011-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Tricyclic Compounds
Pyrimidinone Compounds
Safety Tensioning Device
Photovoltaic Module
Cargo Support Beam
Cytokine Inhibitors
Nucleic Acid Complexes
Imidazopyridazine Compounds
Pyrrolopyrimidine Compounds
Automotive Winch
Syk Inhibitors
Multi-Stage Transmission
24 patents (USPTO):Explore Patents

Title: Wei Deng: A Pioneer in Pharmaceutical Innovations

Introduction

Wei Deng, an accomplished inventor based in Shanghai, China, has made significant contributions to the field of pharmaceuticals. With a portfolio that boasts 10 patents, his work focuses on innovative compounds that have potential applications in treating various diseases, including inflammatory and autoimmune conditions, as well as cancer.

Latest Patents

Deng's recent patents include groundbreaking discoveries in the form of imidazopyridazine compounds and pyrrolopyrimidine compounds. The "Imidazopyridazine compounds and their use" patent discloses novel compounds designed to inhibit PIK, with the potential to treat diseases responsive to such inhibition. These compounds offer hope for advancements in addressing inflammatory diseases and cancer through their unique pharmaceutical compositions.

In addition, the "Pyrrolopyrimidine compounds and uses thereof" patent reveals compounds capable of inhibiting JAK kinases. This patent outlines methods for using pyrrolopyrimidine compounds and their potential role in treating disorders, specifically targeting inflammatory diseases and cancer with specially formulated pharmaceutical compositions.

Career Highlights

Wei Deng has worked with prestigious organizations, including Hutchison Medipharma Limited and Purdue Research Foundation. These positions have helped him develop and refine his expertise in pharmaceutical research and innovation, leading to the successful filing of multiple patents.

Collaborations

Throughout his career, Deng has collaborated with notable colleagues such as Wei-Guo Su and Jianguo Ji. These partnerships have fostered an environment of innovation and creativity, contributing to the successful development of his patented inventions.

Conclusion

Wei Deng represents a significant force in the realm of pharmaceutical inventions. With his innovative compounds targeting critical diseases, his work continues to influence and inspire advancements in medical research and treatment options. His commitment to innovation solidifies his status as a leading inventor in the field, and his ongoing contributions are eagerly anticipated by the industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…